Evaluation and Management of Urgency and Urge Urinary Incontinence in Men

被引：0

作者：

Hollander A.B. ^{[1
]}

Gonzalez R.R. ^{[1
]}

机构：

[1] Baylor College of Medicine, Houston, TX, 77030, 6560 Fannin Street

来源：

Current Bladder Dysfunction Reports | 2012年 / 7卷 / 3期

关键词：

Aging; Benign prostatic hyperplasia (BPH); Botulinum toxin A (BOTOX); Evaluation; Lower urinary tract symptoms (LUTS); Management; Men; Mirabegron; Neurogenic bladder; Neuromodulation; Overactive bladder (OAB); PDE5; inhibitor; Posterior tibial nerve stimulation (PTNS); Tadalafil; Urge incontinence; Urgency; Urodynamics;

D O I：

10.1007/s11884-012-0143-x

中图分类号：

学科分类号：

摘要：

The overactive bladder (OAB) syndrome is increasingly being recognized as a major contributor to the lower urinary tract symptoms in men previously thought to be only due to bladder outlet obstruction from benign prostatic hyperplasia. Medical and surgical treatments that have historically been used to treat women with OAB are being applied to men with great efficacy and a good safety profile. Additionally, treatments such as the β-3 agonist mirabegron, phosphodiesterase-5 inhibitors, sacral and peripheral neuromodulation, and intravesical botulinum toxin injection are promising emerging therapies for the OAB syndrome. This review discusses the evaluation of the male patient with OAB symptoms such as urgency and urge incontinence, and explores the different therapeutic options available for management of men with OAB. © 2012 Springer Science+Business Media, LLC.

引用

页码：230 / 234

页数：4

共 23 条

[1]

Milsom I., Abrams P., Cardozo L., Et al., How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study, BJU Int, 87, pp. 760-766, (2001)

[2]

Hyman M.J., Groutz A., Blaivas J.G., Detrusor instability in men: correlation of lower urinary tract symptoms with urodynamic findings, J Urol, 166, pp. 550-552, (2001)

[3]

Herbison P., Hay-Smith J., Ellis G., Et al., Effectiveness of anticholinergic drugs compared with placebo in the treat- ment of overactive bladder: systematic review, Bmj, 326, pp. 841-844, (2004)

[4]

Nitti V., Herschorn S., Auerbach S., Et al., The Selective Beta-3 Adrenoreceptor Agonist Mirabegron is Effective and Well Tolerated In Patients With Overactive Bladder Syndrome. AUA 2011 Abstract 1958. This Double-blinded, Placebo-controlled Trial Establishes Mirabegron As the First New Class of Drugs For the OAB Syndrome In a Number of Years

[5]

Nitti V., Herschorn S., Auerbach S., Et al., Mirabegron improves patient-reported outcomes in patients with overactive bladder syndrome - results from a North-American study, AUA 2011 Abstract, (1959)

[6]

Resnick N.M., Yalla S.V., Detrusor hyperactivity with impaired contractile function: an unrecognized but common cause of incontinence in elderly patients, Jama, 257, pp. 3076-3081, (1987)

[7]

Athanasopoulos A., Gyftopoulos K., Giannitsas K., Et al., Combination treatment with an alpha-blocker plus an anticholinergic for bladder outlet obstruction: a prospective, randomized, controlled study, J Urol, 169, pp. 2253-2256, (2003)

[8]

van Venrooij G.E., van Melick H.H., Eckhardt M.D., Et al., Correlations of urodynamic changes with changes in symptoms and well-being after transurethral resection of the prostate, J Urol, 168, pp. 605-609, (2002)

[9]

Gacci M., Eardley I., Giuliano F., Et al., Critical analysis of the relationship between sexual dysfunctions and lower urinary tract symptoms due to benign prostatic hyperplasia, Eur Urol, 60, pp. 809-825, (2011)

[10]

Fibbi B., Morelli A., Vignozzi L., Et al., Characterization of phosphodiesterase type 5 expression and functional activity in the human male lower urinary tract, J Sex Med, 7, pp. 59-69, (2010)

← 1 2 3 →